QTXB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
QTXB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Quantrx Biomedical's Free Cash Flow per Share for the three months ended in Sep. 2022 was $0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
For the Medical Instruments & Supplies subindustry, Quantrx Biomedical's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Quantrx Biomedical's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Quantrx Biomedical's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
Quantrx Biomedical (OTCPK:QTXB) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Thank you for viewing the detailed overview of Quantrx Biomedical's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael S Abrams | director | 64 RAMSHEAD ROAD, RAYNHAM MA 02767 |
Patrick T Mooney | director | C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038 |
Robert G. Pinco | director | 1700 K STREET NW, SUITE 300, WASHINGTON DC 20006 |
Hayes Arthur H Jr | director | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Matthew Balk | 10 percent owner | 229 WEST 60TH STREET, NEW YORK NY 10023 |
Evan Levine | director, 10 percent owner | 1517 SAN JACINTO ST., HOUSTON TX 77002 |
Hayes Arthur Hull Jr | director | C/O QUANTRX BIOMEDICAL CORPORATION, 100 S. MAIN STREET, SUITE 300, DOYLESTOWN PA 18901 |
Cindy Horton | officer: V.P. of Diagnostics | 209 BRITTANY PARK, ANDERSON SC 29621 |
Sasha Afanassiev | officer: Officer | 120 GARRISON COURT, LANGHORNE PA 19047 |
Shalom Hirschman | officer: Officer | 5240 BLACKSTONE AVENUE, RIVERDALE NY 10471 |
William H Fleming | director, officer: Secretary | |
Walter W Witoshkin | director, officer: President and CEO | 321 NORRISTOWN ROAD, SUITE 230, AMBLE PA 19002 |
Mark Capital Llc | 10 percent owner | 5173 SEAGROVE PLACE, SAN DIEGO CA 92130 |
Sherbrooke Partners, Llc | 10 percent owner | 570 LEXINGTON AVENUE, FLOOR 3, NEW YORK NY 10022 |
Goldman Sachs & Co. Llc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.